Loading...
Market
First region to approve semaglutide for liver disease by end of 2025
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
Other regions • 25%
No approval by end of 2025 • 25%
Official announcements from regulatory bodies
Story
Novo Nordisk's Semaglutide Shows Promise in 72-Week Phase 3 Liver Disease Trial with MASH Resolution
Nov 1, 2024, 12:17 PM
Novo Nordisk's semaglutide 2.4 mg has demonstrated significant improvements in liver fibrosis and MASH resolution in its phase 3 ESSENCE trial. The trial, which included 1,200 adults, showed that after 72 weeks, 37% of patients treated with semaglutide experienced fibrosis improvement compared to 22.5% on placebo. Additionally, 62.9% of patients achieved MASH resolution, compared to 34.1% on placebo. The drug also showed a positive safety profile. Novo Nordisk plans to file for regulatory approvals in the US and EU in the first half of 2025. Detailed results from the ESSENCE trial will be presented at an upcoming scientific conference.
View original story
Similar markets
Diabetic Macular Edema • 25%
Metabolic Liver Dysfunction • 25%
Addiction Treatment • 25%
Other • 25%
Obstructive Sleep Apnea • 25%
Alzheimer's Disease • 25%
Metabolic Liver Dysfunction • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
Asia-Pacific • 25%
Other regions • 25%
Yes • 50%
No • 50%
Canada • 25%
European Union • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Type 2 Diabetes • 25%
Obesity • 25%
Knee Pain from Osteoarthritis • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%